Table 2. Adverse events in quarantine.
| Number of adverse events in all volunteers (n=36) | Number of adverse events by infection status | Number of adverse events by dose group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Transiently infected (n=5) | Uninfected (n=31) | 1×101 TCID50 (n=8) | 1×102 TCID50 (n=7) | 1×103 TCID50 (n=6) | 1×104 TCID50 (n=7) | 1×105 TCID50 (n=8) | |||
| Fatigue | |||||||||
| Mild | 16 (44%) | 2 (40%) | 14 (45%) | 6 (75%) | 3 (43%) | 3 (50%) | 2 (29%) | 2 (25%) | |
| Moderate | 1 (3%) | 1 (20%) | 0 | 0 | 0 | 0 | 1 (14%) | 0 | |
| Stuffy nose | |||||||||
| Mild | 16 (44%) | 3 (60%) | 13 (42%) | 3 (38%) | 2 (29%) | 3 (50%) | 5 (71%) | 3 (38%) | |
| Headache | |||||||||
| Mild | 10 (28%) | 1 (20%) | 9 (29%) | 4 (5%) | 1 (14%) | 1 (17%) | 4 (57%) | 0 | |
| Moderate | 2 (6%) | 0 | 2 (6%) | 0 | 2 (29%) | 0 | 0 | 0 | |
| Sore throat | |||||||||
| Mild | 9 (25%) | 2 (40%) | 7 (23%) | 1 (13%) | 3 (43%) | 2 (33%) | 3 (43%) | 0 | |
| Moderate | 1 (3%) | 0 | 1 (3%) | 0 | 0 | 1 (17%) | 0 | 0 | |
| Runny nose | |||||||||
| Mild | 8 (22%) | 1 (20%) | 7 (23%) | 1 (13%) | 1 (14%) | 1 (17%) | 2 (29%) | 3 (38%) | |
| Sneezing | |||||||||
| Mild | 8 (22%) | 3 (60%) | 5 (16%) | 2 (25%) | 1 (14%) | 0 | 3 (43%) | 2 (25%) | |
| Muscle pains | |||||||||
| Mild | 7 (19%) | 0 | 7 (23%) | 1 (13%) | 1 (14%) | 2 (33%) | 1 (14%) | 2 (25%) | |
| Sore eyes | |||||||||
| Mild | 5 (14%) | 1 (20%) | 4 (13%) | 1 (13%) | 2 (29%) | 2 (33%) | 0 | 0 | |
| Moderate | 1 (3%) | 0 | 1 (3%) | 0 | 0 | 1 (17%) | 0 | 0 | |
| Tickly throat | |||||||||
| Mild | 5 (14%) | 1 (20%) | 4 (13%) | 0 | 0 | 2 (33%) | 2 (29%) | 1 (13%) | |
| Cough | |||||||||
| Mild | 4 (11%) | 0 | 4 (13%) | 0 | 1 (14%) | 1 (17%) | 2 (29%) | 0 | |
| Change in sense of smell or taste | |||||||||
| Mild | 4 (11%) | 0 | 4 (13%) | 1 (13%) | 0 | 2 (33%) | 1 (14%) | 0 | |
| Toothache | |||||||||
| Severe | 1 (3%)* | 0 | 1 (3%)* | 0 | 0 | 0 | 1 (14%)* | 0 | |
Symptom scores were collected using self-reported symptom diaries twice daily from all volunteers and graded as mild, moderate, or severe. Number of adverse events during the quarantine period (within 14 days of SARS-CoV-2 inoculation) by the maximum grade reported, showing all adverse events reported by ≥ 10% of volunteers and all severe adverse events regardless of frequency. *Unsolicited adverse event deemed unrelated to SARS-CoV-2 inoculation: dental infection in an uninfected participant successfully treated with oral antibiotics in quarantine.